<DOC>
	<DOCNO>NCT03011125</DOCNO>
	<brief_summary>This single center , randomize , double-blind , dose-escalation , placebo-controlled phase 1 clinical trial . This study determine safety side-effect profile investigational dexlansoprazole injection single intravenous administration healthy Chinese adult .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Tolerability Dexlansoprazole Injection Healthy Chinese Adults ( Part 1 )</brief_title>
	<detailed_description>This single center , double-blind , dose-escalation , placebo-controlled clinical trial . Dose escalation proceed accord 3+3 design five predefined dose group . After completion 90mg dosing study , dose-escalation stop , even though MTD observe . A total 28 participant schedule recruit . The whole follow-up period participant 3 day .</detailed_description>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Age ≥18 Years ; Male ( weight ≥50kg ) female ( weight ≥45kg ) ; BMI 19~28 kg/m2 ; Healthy subject ( screen ) ; Subject totally understand aim progress clinical trial , make decision his/her free , signed consent form follow progress . Allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator ; Subject past present history serious disease , include ( limited ) digestive , cardiovascular , respiratory , urinary , musculoskeletal , endocrine , psychiatric neurological , hematologic , immunological metabolic disorder ; Medical examination , laboratory test ECG judge investigator differ significantly normal clinical value ; HIV , HBV , syphilis positive ; Drug dependency abuse ; Heavy smoker ( &gt; 5 cigarette per day ) ; Alcohol use ; Participation another study investigational drug within last 3 month precede study ; Blood donation within last 2 month ( &gt; = 400 ml ) , plan donate blood within 1 month study ; Intake drug might influence result trial two week previous start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>